دورية أكاديمية
Metabolic programming of organ-specific natural killer cell responses.
| العنوان: | Metabolic programming of organ-specific natural killer cell responses. |
|---|---|
| المؤلفون: | Delconte RB; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Sun JC; Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Immunology and Microbial Pathogenesis, Weill Cornell Medical College, New York, New York, USA. |
| المصدر: | Immunological reviews [Immunol Rev] 2024 May; Vol. 323 (1), pp. 8-18. Date of Electronic Publication: 2024 Apr 17. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Country of Publication: England NLM ID: 7702118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-065X (Electronic) Linking ISSN: 01052896 NLM ISO Abbreviation: Immunol Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2002-> : Oxford : Blackwell Original Publication: Copenhagen, Munksgaard. |
| مواضيع طبية MeSH: | Killer Cells, Natural*/immunology , Killer Cells, Natural*/metabolism, Humans ; Animals ; Immunity, Innate ; Organ Specificity/immunology ; Neoplasms/immunology ; Neoplasms/metabolism ; Energy Metabolism ; Tumor Microenvironment/immunology ; Homeostasis ; Cytokines/metabolism ; Metabolic Reprogramming |
| مستخلص: | Cells of the mammalian innate immune system have evolved to protect the host from various environmental or internal insults and injuries which perturb the homeostatic state of the organism. Among the lymphocytes of the innate immune system are natural killer (NK) cells, which circulate and survey host tissues for signs of stress, including infection or transformation. NK cells rapidly eliminate damaged cells in the blood or within tissues through secretion of cytolytic machinery and production of proinflammatory cytokines. To perform these effector functions while traversing between the blood and tissues, patrolling NK cells require sufficient fuel to meet their energetic demands. Here, we highlight the ability of NK cells to metabolically adapt across tissues, during times of nutrient deprivation and within tumor microenvironments. Whether at steady state, or during viral infection and cancer, NK cells readily shift their nutrient uptake and usage in order to maintain metabolism, survival, and function. (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.) |
| References: | Nat Immunol. 2018 Sep;19(9):963-972. (PMID: 30082830) Sci Immunol. 2022 Apr 8;7(70):eabi8642. (PMID: 35394814) J Immunol. 2013 Dec 1;191(11):5684-94. (PMID: 24184559) Nature. 2022 Sep;609(7928):801-807. (PMID: 35901960) Lab Anim. 2013 Oct;47(4):225-40. (PMID: 24025567) Nat Rev Cancer. 2013 Apr;13(4):227-32. (PMID: 23446547) Nat Immunol. 2008 May;9(5):495-502. (PMID: 18425106) Immunity. 2016 Aug 16;45(2):428-41. (PMID: 27496734) Nat Immunol. 2009 Apr;10(4):403-11. (PMID: 19252491) Cell. 2015 Sep 10;162(6):1229-41. (PMID: 26321679) Proc Natl Acad Sci U S A. 2024 Mar 12;121(11):e2319254121. (PMID: 38442180) Trends Cancer. 2023 Mar;9(3):212-222. (PMID: 36646607) Cell Rep. 2021 Jun 1;35(9):109210. (PMID: 34077737) Immunity. 2024 Jan 9;57(1):124-140.e7. (PMID: 38157853) Front Physiol. 2022 Mar 16;13:862458. (PMID: 35370761) Cell Rep. 2020 Mar 10;30(10):3566-3582.e4. (PMID: 32160557) Nat Immunol. 2023 Oct;24(10):1685-1697. (PMID: 37697097) Immunity. 2016 May 17;44(5):1127-39. (PMID: 27156386) Cancer Immunol Res. 2019 Jul;7(7):1162-1174. (PMID: 31088844) Cancer Discov. 2015 Oct;5(10):1024-39. (PMID: 26382145) Trends Immunol. 2021 May;42(5):389-400. (PMID: 33865714) Immunity. 2014 Jun 19;40(6):833-42. (PMID: 24950203) Immunity. 2022 Feb 8;55(2):210-223. (PMID: 35139351) Cancer Immunol Res. 2019 Feb;7(2):335-346. (PMID: 30563827) Annu Rev Immunol. 2021 Apr 26;39:417-447. (PMID: 33902312) Cancer Cell. 2016 Jul 11;30(1):136-146. (PMID: 27411588) Cell. 2019 Aug 22;178(5):1088-1101.e15. (PMID: 31442402) Cell Stem Cell. 2014 Jun 5;14(6):810-23. (PMID: 24905167) Blood. 2011 Apr 28;117(17):4467-75. (PMID: 21364193) Nat Immunol. 2014 Aug;15(8):749-757. (PMID: 24973821) J Clin Invest. 2003 Dec;112(12):1821-30. (PMID: 14679177) Cell Metab. 2016 Nov 8;24(5):657-671. (PMID: 27641098) Cell Cycle. 2014;13(21):3315-6. (PMID: 25485573) J Clin Invest. 2003 Dec;112(12):1785-8. (PMID: 14679172) PLoS One. 2015 Jun 17;10(6):e0130357. (PMID: 26083629) Eur J Cancer. 2011 Jan;47(1):33-43. (PMID: 20889333) Leukemia. 2012 Sep;26(9):2019-26. (PMID: 22446501) Cell Metab. 2016 Apr 12;23(4):685-98. (PMID: 27050305) Immunity. 2021 Oct 12;54(10):2288-2304.e7. (PMID: 34437840) Annu Rev Immunol. 2005;23:225-74. (PMID: 15771571) Acta Sci Pol Technol Aliment. 2014 Apr-Jun;13(2):191-202. (PMID: 24876314) Nat Rev Cancer. 2022 Oct;22(10):557-575. (PMID: 35879429) Sci Signal. 2014 Jul 01;7(332):re2. (PMID: 24985347) Immunity. 2023 Sep 12;56(9):2173-2174. (PMID: 37703831) J Lipid Res. 2015 Jul;56(7):1271-81. (PMID: 26014962) Bone. 2019 Jan;118:32-41. (PMID: 29360620) Nature. 2017 Jun 1;546(7656):158-161. (PMID: 28538737) Immunity. 2018 May 15;48(5):992-1005.e8. (PMID: 29768180) Front Immunol. 2020 Aug 28;11:1989. (PMID: 32983138) J Immunol. 2015 Feb 15;194(4):1954-62. (PMID: 25595780) Immunity. 2023 Apr 11;56(4):783-796.e7. (PMID: 36827982) Am J Physiol Endocrinol Metab. 2002 Dec;283(6):E1185-91. (PMID: 12388154) Cell. 2019 Aug 22;178(5):1102-1114.e17. (PMID: 31442403) Immunity. 2020 Jun 16;52(6):1075-1087.e8. (PMID: 32445619) Eur J Cancer. 2022 Sep;172:300-310. (PMID: 35810555) Nutr Metab (Lond). 2017 Jan 5;14:3. (PMID: 28070205) Nat Aging. 2021 Jan;1(1):47-59. (PMID: 35310455) Cell Metab. 2021 Jun 1;33(6):1205-1220.e5. (PMID: 33852875) Oncotarget. 2015 May 20;6(14):11806-19. (PMID: 25909219) Nat Commun. 2018 Jun 14;9(1):2341. (PMID: 29904050) Elife. 2014 Jan 01;3:e01659. (PMID: 24714492) Annu Rev Immunol. 2018 Apr 26;36:461-488. (PMID: 29677474) Nature. 2009 Jul 2;460(7251):103-7. (PMID: 19494812) Nature. 2019 Jul;571(7764):211-218. (PMID: 31207603) PLoS One. 2013 Sep 06;8(9):e72449. (PMID: 24039766) Cell Metab. 2017 Feb 7;25(2):262-284. (PMID: 28178565) Nat Immunol. 2015 Apr;16(4):376-85. (PMID: 25729921) Metabolism. 2007 Nov;56(11):1500-7. (PMID: 17950100) Front Immunol. 2019 Dec 13;10:2915. (PMID: 31921174) Front Immunol. 2018 Nov 09;9:2569. (PMID: 30473697) Cell Metab. 2018 Sep 4;28(3):504-515.e7. (PMID: 30043753) Nat Immunol. 2007 Dec;8(12):1337-44. (PMID: 17965716) Immunity. 2023 Jun 13;56(6):1341-1358.e11. (PMID: 37315536) Signal Transduct Target Ther. 2022 Jun 29;7(1):205. (PMID: 35768424) Sci Transl Med. 2012 Mar 7;4(124):124ra27. (PMID: 22323820) Nat Immunol. 2017 Sep;18(9):995-1003. (PMID: 28759002) Nat Immunol. 2017 Nov;18(11):1197-1206. (PMID: 28920951) Nat Immunol. 2014 Dec;15(12):1152-61. (PMID: 25362489) Oncologist. 2009 Mar;14(3):240-52. (PMID: 19289488) Pancreas. 2017 Apr;46(4):476-481. (PMID: 28230660) Elife. 2014 Nov 11;3:. (PMID: 25385531) Blood. 2009 May 28;113(22):5488-96. (PMID: 19234143) Immunity. 2015 Aug 18;43(2):331-42. (PMID: 26253785) Cell Metab. 2023 Sep 5;35(9):1497-1499. (PMID: 37673035) Nat Immunol. 2017 Sep;18(9):1004-1015. (PMID: 28759001) Immunity. 2017 Feb 21;46(2):273-286. (PMID: 28228283) Cancer Discov. 2022 Jan;12(1):90-107. (PMID: 34789537) Science. 2019 Mar 1;363(6430):989-993. (PMID: 30819964) J Immunol. 2013 Aug 1;191(3):1486-95. (PMID: 23817426) Nat Immunol. 2021 Oct;22(10):1256-1267. (PMID: 34462601) Cell Rep. 2020 Jan 28;30(4):949-958.e6. (PMID: 31995765) J Clin Invest. 2003 Dec;112(12):1796-808. (PMID: 14679176) Cancer Res. 2018 Feb 15;78(4):1003-1016. (PMID: 29229601) Cell. 2019 Aug 22;178(5):1072-1087.e14. (PMID: 31442401) Cell. 2018 Feb 22;172(5):1022-1037.e14. (PMID: 29429633) J Immunol. 2014 Nov 1;193(9):4477-84. (PMID: 25261477) Nutr Diabetes. 2014 Mar 24;4:e113. (PMID: 24662749) |
| معلومات مُعتمدة: | R01 AI100874 United States AI NIAID NIH HHS; AI155558 United States HI NHLBI NIH HHS; P30 CA008748 United States CA NCI NIH HHS; United States CRI Cancer Research Institute; AI100874 United States HI NHLBI NIH HHS; National Health and Medical Research Council; AI130043 United States HI NHLBI NIH HHS; P30CA008748 United States HI NHLBI NIH HHS; R01 AI155558 United States AI NIAID NIH HHS; Burroughs Wellcome Fund; Parker Institute for Cancer Immunotherapy; American Cancer Society; R01 AI130043 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: NK cells; cancer; immunity; immunometabolism |
| تواريخ الأحداث: | Date Created: 20240417 Date Completed: 20240517 Latest Revision: 20240520 |
| رمز التحديث: | 20240520 |
| مُعرف محوري في PubMed: | PMC11102308 |
| DOI: | 10.1111/imr.13333 |
| PMID: | 38628147 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1600-065X |
|---|---|
| DOI: | 10.1111/imr.13333 |